98%
921
2 minutes
20
Some antibiotics that are frequently employed are -lactams. In light of the hydrolytic process of -lactamase, found in Gram-negative bacteria, inhibitors of -lactamase (BLIs) have been produced. Examples of first-generation -lactamase inhibitors include sulbactam, clavulanic acid, and tazobactam. Many kinds of bacteria immune to inhibitors have appeared, and none cover all the -lactamase classes. Various methods have been utilized to develop second-generation -lactamase inhibitors possessing new structures and facilitate the formation of diazabicyclooctane (DBO), cyclic boronate, metallo-, and dual-nature -lactamase inhibitors. This review describes numerous promising second-generation -lactamase inhibitors, including vaborbactam, avibactam, and cyclic boronate serine--lactamase inhibitors. Furthermore, it covers developments and methods for synthesizing ML (metallo--lactamase inhibitors), which are clinically effective, as well as the various dual-nature-based inhibitors of -lactamases that have been developed. Several combinations are still only used in preclinical or clinical research, although only a few are currently used in clinics. This review comprises materials on the research progress of BLIs over the last five years. It highlights the ongoing need to produce new and unique BLIs to counter the appearance of multidrug-resistant bacteria. At present, second-generation BLIs represent an efficient and successful strategy.
Download full-text PDF |
Source |
---|---|
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC11434895 | PMC |
http://dx.doi.org/10.3390/ph17091108 | DOI Listing |
Microbiol Spectr
September 2025
Division of Infectious Diseases, Department of Medicine, University of Texas at Tyler School of Medicine, Tyler, Texas, USA.
Despite the long therapy duration, the treatment outcomes for lung disease (MAB-LD) are very poor. β-Lactams are among the recommended drugs for the treatment of MAB-LD; however, they are prone to hydrolysis by MAB β-lactamase enzymes. Therefore, β-lactamase inhibitors have been developed to overcome this problem.
View Article and Find Full Text PDFRSC Med Chem
August 2025
School of Cellular and Molecular Medicine, University of Bristol Bristol BS8 1TD UK
Carbapenemases, β-lactamases hydrolysing carbapenem antibiotics, challenge the treatment of multi-drug resistant bacteria. The OXA-48 carbapenemase is widely disseminated in , necessitating new treatments for producer strains. Diazabicyclooctane (DBO) inhibitors, including avibactam and nacubactam, act on a wide range of enzymes to overcome β-lactamase-mediated resistance.
View Article and Find Full Text PDFCurr Opin Infect Dis
September 2025
Infectious Diseases Unit, IRCCS Azienda Ospedaliero-Universitaria di Bologna.
Purpose Of Review: Sulbactam-durlobactam (SUL-DUR) is a novel β-lactam/β-lactamase inhibitor combination recently approved for carbapenem-resistant Acinetobacter baumannii (CRAB) infections. This review summarizes current knowledge on the optimal use of SUL-DUR, whether administered alone or in combination with carbapenems, particularly imipenem.
Recent Findings: Data from registrational trial demonstrate that SUL-DUR is an effective and well tolerated treatment option for CRAB severe infections.
In Silico Pharmacol
September 2025
Institute of Bioresources and Sustainable Development, Takyelpat, Imphal, 795001 Manipur India.
Abstract: The rise of multidrug-resistant poses significant challenges in hospital settings. This study evaluates the antimicrobial potential of the aqueous extract of (AETC) against strain AB0014, isolated from a preterm neonate presenting sepsis. The minimum inhibitory concentration (MIC) was determined using the microdilution method.
View Article and Find Full Text PDFIn Silico Pharmacol
September 2025
Medical Sciences Research Center, Ghalib University, Kabul, Afghanistan.
Unlabelled: The rise of β-lactamase-mediated resistance in Gram-negative pathogens has created an urgent need for novel inhibitors to preserve antibiotic efficacy. This study explores the potential of curcumin, a natural polyphenol with known antimicrobial properties, as a broad-spectrum inhibitor of class A serine-β-lactamases (SBLs) through comprehensive computational analysis. Using molecular docking, 200 ns molecular dynamics simulations, and binding energy calculations, we investigated curcumin's interactions with three clinically important SBLs: KPC-3, CTX-M-15, and L2.
View Article and Find Full Text PDF